CTRI/2013/04/003594已完成4 期
An open label study to evaluate the effectiveness, safety and tolerability of Dhathri Hair Care Herbal Oil in comparison with Coconut Oil in the management of alopecia and seborrheic dermatitis of the scalp in adults
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects between the age group of 21 to 45 years.
- •2. Subjects who are able to give written informed consent and ready to comply with the protocol.
- •3. Subjects with active alopecia, and seborrheic dermatitis of the scalp â?? â??Total ASFS Score >= 16
- •4. Subjects with a minimum hair length of 2 inches and willing to maintain the same minimum length, hair style until the end of the study.
排除标准
- •1. Subjects on topical treatment for alopecia and seborrheic dermatitis for 4 weeks prior to enrollment.
- •2. Subject with other dermatological disorders of the scalp that might interfere with the study evaluation.
- •3. Subjects with significant scalp scarring.
- •4. Subjects who have anemia or iron deficiency.
- •5. Subjects who have previously undergone hair transplantation procedures.
- •6. History of systemic or cutaneous malignancy or evidence of immunocompromised state.
- •7. Subjects with history of skin allergy.
- •8. Subjects on systemic steroids for more than 14 days within 2 months prior to enrollment.
- •9. Female subjects who are reported pregnant/planning a pregnancy or lactating.
- •10. Subjects who are currently enrolled in an active investigational study or have participated in an investigational study within 30 days prior to enrollment.
- •11. Subjects, who in the opinion of the Investigator or the Expert Dermatologist are not eligible for enrollment in the study.
研究者
相似试验
进行中（未招募）
1 期
Investigation on the effect and tolerability of erenumab in posttraumatic headachePost-traumatic headacheMedDRA version: 20.0Level: LLTClassification code 10019222Term: Headache post-traumaticSystem Organ Class: 100000004852EUCTR2018-003943-46-DKDanish Headache Center100
进行中（未招募）
1 期
An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea - STOP ROS StudyEUCTR2019-003971-20-DKRigshospitalet Glostrup30
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 18.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 18.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-ESRoche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd600
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-IEF. Hoffmann-La Roche Ltd680
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-GBF. Hoffmann-La Roche Ltd750